Welcome to our dedicated page for Eyenovia news (Ticker: EYEN), a resource for investors and traders seeking the latest updates and insights on Eyenovia stock.
Eyenovia, Inc. (EYEN), which has adopted the corporate name Hyperion DeFi, Inc., generates news that spans both ophthalmic technology and digital asset markets. Company announcements describe a dual focus: development and commercialization of advanced topical eye treatments using its proprietary Optejet dispensing platform, and the build-out of a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain.
On this news page, readers can follow updates on Eyenovia’s transition to Hyperion DeFi, including the reported name change and anticipated ticker change from EYEN to HYPD on the Nasdaq Capital Market. Releases detail the company’s private placement financing to acquire HYPE, launch of a co-branded Hyperliquid validator with Kinetiq, and broader onchain engagement strategy, including staking and validator operations supported by infrastructure provider Pier Two.
Investors and observers can also review ophthalmic-focused news, such as progress reports on the Optejet User Filled Device (UFD), verification and validation milestones, and plans for regulatory submissions. Additional items include updates on potential strategic transactions, such as a contemplated reverse merger with Betaliq, as well as information on existing FDA-approved products like clobetasol propionate ophthalmic suspension, 0.05% and Mydcombi for mydriasis.
Together, these news items provide insight into how the company is combining an ophthalmic technology platform with a cryptocurrency treasury reserve strategy centered on HYPE. For users tracking EYEN, this page offers a consolidated view of corporate actions, financing developments, product updates and blockchain-related initiatives described by the company in its press releases.
Eyenovia, Inc. (NASDAQ: EYEN), a clinical-stage ophthalmic biopharmaceutical firm, is set to release its financial results for Q1 2020 on May 13, 2020, post-market close. Dr. Sean Ianchulev, CEO, alongside CFO John Gandolfo and VP Michael Rowe, will conduct a conference call at 4:45 PM ET to discuss the results. The call can be accessed by dialing 1-866-916-2921 (US) or 1-210-874-7771 (International), using conference code 4397339. The event will also be streamed live on Eyenovia's investor relations webpage and archived for one year.